Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
colchicine + minocycline
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of colchicine and minocycline used primarily for the treatment of hidradenitis suppurativa (HS). This combination leverages the anti-inflammatory properties of both medications to control disease progression. The standard regimen consists of 100 mg minocycline administered orally once per day in combination with 0.5 mg colchicine administered twice per day for 6 months, followed by a maintenance regimen of 0.5 mg colchicine administered orally twice per day for 3 months.
02
Targets
Bacterial RibosomeMMP9 (Matrix metalloproteinase-9)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on colchicine + minocycline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on colchicine + minocycline.